| CCR2 |
| LOCUS ID | 729230 | ||||||||||||||||
| GENE_SYMBOL | CCR2 | ||||||||||||||||
| GENE NAME | chemokine (C-C motif | ||||||||||||||||
| SYNONYMNS | CKR2, CCR-2, CCR2A, CCR2B, CD192, CKR2A, CKR2B, CMKBR2, MCP-1-R, CC-CKR-2 | ||||||||||||||||
| CHROMOSOME | 3 | ||||||||||||||||
| HOMOLOGENE ID | 537 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| This gene encodes two isoforms of a receptor for monocyte chemoattractant protein-1, a chemokine which specifically mediates monocyte chemotaxis. Monocyte chemoattractant protein-1 is involved in monocyte infiltration in inflammatory diseases such as rheumatoid arthritis as well as in the inflammatory response against tumors. The receptors encoded by this gene mediate agonist-dependent calcium mobilization and inhibition of adenylyl cyclase. This gene is located in the chemokine receptor gene cl |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Nephropathy | 1. The novel CCR2 antagonist CCX140-B, which is currently in two separate phase 2 clinical trials in diabetic nephropathy, has recently been shown to reduce hemoglobin A1c and fasting blood glucose levels in type 2 diabetics. | 23986513 |
| Atherosclerosis | 1. These data show that AGE-LDL can increase CCR2 expression in macrophages and stimulate the chemotactic response elicited by MCP-1. This novel mechanism may contribute to accelerated atherogenesis in diabetic patients. | 18164016 |
| Insulin resistance and inflammation | 1. In obese mice matched for adiposity, Ccr2 deficiency reduced macrophage content and the inflammatory profile of adipose tissue, increased adiponectin expression, ameliorated hepatic steatosis, and improved systemic glucose homeostasis and insulin sensitivity. | 16341265 |